FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080321631> ?p ?o ?g. }

• W2080321631 endingPage "536" @default.
• W2080321631 startingPage "535" @default.
• W2080321631 abstract "The worldwide annual incidence of squamous cell carcinomas of the head and neck (HNSCCs) is about 500,000. The prognosis of these patients is based mainly on the clinicopathological tumor stage, in particular the lymph node status pN, even though it is generally accepted that outcomes can be different among tumors of the same stage. Therefore, our study focused on the identification of molecular parameters for the improvement of the daily clinical diagnosis, which contributes to further prognostic differentiation. Polo-like kinases (PLKs) have been implicated in the regulation of the eukaryotic cell cycle (Lane and Nigg, 1997). Expression of PLK mRNA, a novel marker for cellular proliferation, correlates with the prognosis of patients suffering from different types of tumor (Holtrich et al., 1994; Wolf et al., 1997; Knecht et al., 1999). We have examined the prognostic role of PLK-protein expression in human cancer. Primary tumors from 157 patients with HNSCC, collected over a period of 1 year, were evaluated for PLK immunoreactivity. Therapeutic and post-therapeutic investigations (5 years) of patients (115 male, 42 female) suffering from oropharyngeal carcinomas (stage I = 14, stage II = 30, stage III = 34, stage IV = 79) were performed as follows. Patients in tumor stages I and II underwent surgery, whereas patients in stages III and IV were subjected to surgery and post-operative radiotherapy (2 Gy fractions given as once-a-day treatment to a total dose of 70 Gy applied to the primary region and the neck). Chemotherapy was given non-concomitantly, using 3 cycles of cisplatin (20 mg/qm) and 5-fluorouracil (1,000 mg/qm) according to a standard schedule (Forastiere et al., 1992). Tumor recurrences were treated chemotherapeutically with the same regimen until no response or progressive disease was measured in 2 dimensions by computed tomography. The length of follow-up was between 5 and 132 months. Paraffin-embedded tumor sections were immunolabeled with an affinity-purified PLK-specific, polyclonal rabbit serum. The primary antibody, diluted 1:80, was visualized by the APAAP technique; sections were counterstained with hematoxylin. For comparative purposes, sections were labeled with antibodies for Ki67 (1:50; Dako, Hamburg, Germany) and PCNA (1:1,000; Dako) using the same technique. Three independent investigators calculated the number of tumor cells (stained nuclei) positive for PLK, Ki67 or PCNA, respectively, per 5,000 tumor cells. A minimum of 15 fields (400×) per tumor were investigated. Prognostic evaluations were based on the mean PLK index (positive cells/5,000 cells × 100). Levels of PLK protein in microscopically normal oropharyngeal mucosa (median = 12.0%, minimum = 0.1%, maximum = 41.0%) surrounding a tumor were low. In 10% of the investigated cases, we observed in the surrounding tissue (within 3 to 5 cm of the tumor) dysplasia (grade I/II). Under these conditions, levels of PLK-protein expression were slightly elevated. Compared to the periphery, PLK protein was over-expressed (median = 59.4%, minimum = 22.3%, maximum = 74.8%) in oropharyngeal carcinomas (Wilcoxon's test, p = 0.016). A correlation of PLK expression with clinicopathological parameters led to further significant correlations with pathological tumor stage (p = 0.007) and pN stage (p = 0.012) but not with N stage (p = 0.09, Kruskal-Wallis test). A Kaplan-Meier analysis based on a median cut-off showed that patients exhibiting moderate PLK expression (<59.4%) had longer survival times than those exhibiting high expression (≥59.4%, log rank p = 0.013; Fig. 1). Median survival times were 52 months [95% confidence interval (CI) 36–67 months] and 26 months (95% CI 14–37 months), respectively. To test the selectivity of PLK prognostic information, we performed a Cox regression analysis. During stepwise backward selection from entered variables (age, sex, pT, pN, PLK expression, therapy), only pN (eB = 1.87, 95% CI 1.14–2.89, p = 0.007) and PLK (eB = 2.31, 95% CI 0.96–5.56, p = 0.039) were significant predictors of survival. In contrast, the proliferation markers Ki67 and PCNA, which are frequently discussed as prognostic parameters for HNSCC, were not associated with tumor stage, pN or survival in our study, which is in line with the results of Sommer and Olofsson (1997). Kaplan-Meier curve of survival of patients with HNSSC (n = 157). Adjusted survival rate is given as a percentage. PLK-expression indices are grouped according to a median of 59.4% into moderate (<59.4%, n = 78) and high (≥59.4%, n = 79). Log-rank test p = 0.013. Based on immunohistochemical methods, PLK appears to be a new prognostic marker for the daily routine diagnosis of the risk of dying for patients with oropharyngeal carcinoma in addition to the pN stage. Moreover, if the pN stage is unknown and the prognostic information relies only on clinical investigations, determination of PLK expression in tumor-derived specimens could improve the prediction of survival. Yours sincerely, Rainald Knecht, Christine Oberhauser, Klaus Strebhardt" @default.
• W2080321631 created "2016-06-24" @default.
• W2080321631 creator A5019378375 @default.
• W2080321631 creator A5047027454 @default.
• W2080321631 creator A5068158443 @default.
• W2080321631 date "2000-01-01" @default.
• W2080321631 modified "2023-10-05" @default.
• W2080321631 title "PLK (polo-like kinase), a new prognostic marker for oropharyngeal carcinomas" @default.
• W2080321631 cites W1952422131 @default.
• W2080321631 cites W2021252415 @default.
• W2080321631 cites W2028513320 @default.
• W2080321631 cites W2053738387 @default.
• W2080321631 doi "https://doi.org/10.1002/1097-0215(20001120)89:6<535::aid-ijc12>3.0.co;2-e" @default.
• W2080321631 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11102900" @default.
• W2080321631 hasPublicationYear "2000" @default.
• W2080321631 type Work @default.
• W2080321631 sameAs 2080321631 @default.
• W2080321631 citedByCount "83" @default.
• W2080321631 countsByYear W20803216312012 @default.
• W2080321631 countsByYear W20803216312013 @default.
• W2080321631 countsByYear W20803216312014 @default.
• W2080321631 countsByYear W20803216312015 @default.
• W2080321631 countsByYear W20803216312016 @default.
• W2080321631 countsByYear W20803216312017 @default.
• W2080321631 countsByYear W20803216312018 @default.
• W2080321631 countsByYear W20803216312019 @default.
• W2080321631 countsByYear W20803216312021 @default.
• W2080321631 countsByYear W20803216312022 @default.
• W2080321631 countsByYear W20803216312023 @default.
• W2080321631 crossrefType "journal-article" @default.
• W2080321631 hasAuthorship W2080321631A5019378375 @default.
• W2080321631 hasAuthorship W2080321631A5047027454 @default.
• W2080321631 hasAuthorship W2080321631A5068158443 @default.
• W2080321631 hasBestOaLocation W20803216311 @default.
• W2080321631 hasConcept C120665830 @default.
• W2080321631 hasConcept C121332964 @default.
• W2080321631 hasConcept C121608353 @default.
• W2080321631 hasConcept C126322002 @default.
• W2080321631 hasConcept C142724271 @default.
• W2080321631 hasConcept C143998085 @default.
• W2080321631 hasConcept C146357865 @default.
• W2080321631 hasConcept C151730666 @default.
• W2080321631 hasConcept C184235292 @default.
• W2080321631 hasConcept C2776530083 @default.
• W2080321631 hasConcept C2776694085 @default.
• W2080321631 hasConcept C2778239845 @default.
• W2080321631 hasConcept C2780849966 @default.
• W2080321631 hasConcept C29537977 @default.
• W2080321631 hasConcept C509974204 @default.
• W2080321631 hasConcept C61511704 @default.
• W2080321631 hasConcept C71924100 @default.
• W2080321631 hasConcept C84815855 @default.
• W2080321631 hasConcept C86803240 @default.
• W2080321631 hasConcept C95444343 @default.
• W2080321631 hasConceptScore W2080321631C120665830 @default.
• W2080321631 hasConceptScore W2080321631C121332964 @default.
• W2080321631 hasConceptScore W2080321631C121608353 @default.
• W2080321631 hasConceptScore W2080321631C126322002 @default.
• W2080321631 hasConceptScore W2080321631C142724271 @default.
• W2080321631 hasConceptScore W2080321631C143998085 @default.
• W2080321631 hasConceptScore W2080321631C146357865 @default.
• W2080321631 hasConceptScore W2080321631C151730666 @default.
• W2080321631 hasConceptScore W2080321631C184235292 @default.
• W2080321631 hasConceptScore W2080321631C2776530083 @default.
• W2080321631 hasConceptScore W2080321631C2776694085 @default.
• W2080321631 hasConceptScore W2080321631C2778239845 @default.
• W2080321631 hasConceptScore W2080321631C2780849966 @default.
• W2080321631 hasConceptScore W2080321631C29537977 @default.
• W2080321631 hasConceptScore W2080321631C509974204 @default.
• W2080321631 hasConceptScore W2080321631C61511704 @default.
• W2080321631 hasConceptScore W2080321631C71924100 @default.
• W2080321631 hasConceptScore W2080321631C84815855 @default.
• W2080321631 hasConceptScore W2080321631C86803240 @default.
• W2080321631 hasConceptScore W2080321631C95444343 @default.
• W2080321631 hasIssue "6" @default.
• W2080321631 hasLocation W20803216311 @default.
• W2080321631 hasLocation W20803216312 @default.
• W2080321631 hasOpenAccess W2080321631 @default.
• W2080321631 hasPrimaryLocation W20803216311 @default.
• W2080321631 hasRelatedWork W1535958986 @default.
• W2080321631 hasRelatedWork W167319750 @default.
• W2080321631 hasRelatedWork W2044379330 @default.
• W2080321631 hasRelatedWork W2323473382 @default.
• W2080321631 hasRelatedWork W2376593068 @default.
• W2080321631 hasRelatedWork W2408650435 @default.
• W2080321631 hasRelatedWork W2414573978 @default.
• W2080321631 hasRelatedWork W363598932 @default.
• W2080321631 hasRelatedWork W4206600817 @default.
• W2080321631 hasRelatedWork W4220939315 @default.
• W2080321631 hasVolume "89" @default.
• W2080321631 isParatext "false" @default.
• W2080321631 isRetracted "false" @default.
• W2080321631 magId "2080321631" @default.
• W2080321631 workType "article" @default.